Mission Therapeutics has attracted one of the highest profile syndicates of investors in Europe. The Company has to date received £87 million in venture capital from a blue chip syndicate of institutional and corporate investors.
History of Investment
2011: Series A funding £7 million ($11 m) was led by Sofinnova Partners, together with Touchstone Innovations, SR One and the Roche Venture Fund.
2013: Series B £20 million ($32 m) equity financing with follow-on investment from all the existing shareholders plus a new investor, Pfizer Venture Investments.
2016: Series C £60 million ($87 m) funding round led by Touchstone Innovations and new investor Woodford Patient Capital Trust with follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments.
Moneta (Building 280)
Babraham Research Campus
T: +44 (0)1223 497 454